Insmed’s 200% rally just hit a brutal wall. The stock crashed 17% after its star drug, Brinsupri, failed a key Phase 2 study—shattering the thesis that it could be a "Swiss Army Knife" for inflammation. Even a surprise acquisition announcement couldn't distract Wall Street from the flop. In this episode, we break down the failed "misdirection" play and analyze the wreckage: Is this a disastrous signal for the rest of the pipeline, or just an overreaction to "spilled gravy" while the core billion-dollar business remains safe?

Ver todos los episodios